BET inhibitors function by binding to the bromodomains of BET proteins, thereby preventing these proteins from interacting with acetylated lysines on histone tails. This interaction is crucial for the regulation of gene transcription. By disrupting this process, BET inhibitors can downregulate the expression of oncogenes and other genes involved in disease progression, leading to reduced tumor growth and potentially inducing apoptosis in cancer cells.
